The IGNYTE continues to show promising outcomes despite negative FDA decisions.
Daniel Olson, MD, discusses the results of a phase 1 trial of brenetasfusp, a PRAME ImmTAC therapy in advanced melanoma.
APP-led benign hematology consults boost access in community oncology—cut wait times, expand capacity, and show how teams scale safely. As community oncology practices continue to face growing patient ...
SENOMAC at ASCO 2026 shows skipping completion ALND in select breast cancer keeps survival high and cuts lymphedema, boosting ...
Durvalumab monotherapy did not meet the prespecified statistical threshold for DFS versus active monitoring, despite a 6-point absolute 3-year DFS difference (78% vs 72%). RAMPART enrolled ...
Five-year OS was 94.4% with ALND omission vs 93.4% with completion ALND (HR 0.89), confirming non-inferiority; breast cancer–specific survival was similarly high in both arms. Inclusion of mastectomy ...
The second is the combination of cutaneous toxicity (rash, paronychia) and venous thromboembolism (VTE), which requires ...
Dr. Rodriguez discusses CNS surveillance for Mr. Smith, who has selected subcutaneous (SC) amivantamab plus lazertinib for ...
Dr. Rodriguez walks through the central nervous system (CNS) efficacy data for the three first-line options. She notes that ...
Dr. Rodriguez describes the current period in EGFR-positive lung cancer as one of active change in the first-line landscape: ...
FDA opens expanded access to daraxonrasib for metastatic pancreatic cancer, as phase 3 data boost survival and clinics race ...
In closing, Dr. Rodriguez emphasizes that for patients who present with brain metastases, first-line treatment selection in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results